BSX Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of 14.45% compared to Boston Scientific's net margin of 30.99%. Boston Scientific's return on equity of 9.57% beat Intuitive Surgical's return on equity of 15.82%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.81%. On the other hand Intuitive Surgical has an analysts' consensus of $578.35 which suggests that it could grow by 12.95%. Given that Boston Scientific has higher upside potential than Intuitive Surgical, analysts believe Boston Scientific is more attractive than Intuitive Surgical.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Boston Scientific's net income of $674M is lower than Intuitive Surgical's net income of $698.4M. Notably, Boston Scientific's price-to-earnings ratio is 75.33x while Intuitive Surgical's PE ratio is 75.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.75x versus 21.33x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 14.45% compared to Boston Scientific's net margin of -5.14%. Boston Scientific's return on equity of 9.57% beat Integer Holdings's return on equity of 4.85%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.81%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 24%. Given that Integer Holdings has higher upside potential than Boston Scientific, analysts believe Integer Holdings is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Integer Holdings quarterly revenues of $437.4M. Boston Scientific's net income of $674M is higher than Integer Holdings's net income of -$22.5M. Notably, Boston Scientific's price-to-earnings ratio is 75.33x while Integer Holdings's PE ratio is 56.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.75x versus 2.42x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 14.45% compared to Boston Scientific's net margin of 6.22%. Boston Scientific's return on equity of 9.57% beat Insulet's return on equity of 36.9%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.81%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 16.14%. Given that Insulet has higher upside potential than Boston Scientific, analysts believe Insulet is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Insulet quarterly revenues of $569M. Boston Scientific's net income of $674M is higher than Insulet's net income of $35.4M. Notably, Boston Scientific's price-to-earnings ratio is 75.33x while Insulet's PE ratio is 52.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.75x versus 9.73x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 14.45% compared to Boston Scientific's net margin of 11.15%. Boston Scientific's return on equity of 9.57% beat Stryker's return on equity of 14.2%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.81%. On the other hand Stryker has an analysts' consensus of $422.35 which suggests that it could grow by 8.45%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.7B, which are smaller than Stryker quarterly revenues of $5.9B. Boston Scientific's net income of $674M is higher than Stryker's net income of $654M. Notably, Boston Scientific's price-to-earnings ratio is 75.33x while Stryker's PE ratio is 52.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.75x versus 6.47x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.